Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 482-490

  Adriaanse, M P M ^a   Tack, G J ^b   Passos, V Lima ^c   Damoiseaux, J G M C ^d   Schreurs, M W J ^b,e   Van Wijck, K ^d   Riedl, R G ^d   Masclee, A A M ^d   Buurman, W A ^d   Mulder, C J J ^b   Vreugdenhil, A C E ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ENDOMYSIUM ANTIBODY; FATTY ACID BINDING PROTEIN 2; IMMUNOGLOBULIN A ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CELIAC DISEASE; CELL DAMAGE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENTEROCYTE DAMAGE; FEMALE; GLUTEN FREE DIET; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE CELL; INTESTINE VILLUS ATROPHY; MAJOR CLINICAL STUDY; MALE; MARSH GRADE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ADULT; AGED; ATROPHY; AUTOANTIBODIES; BIOLOGICAL MARKERS; CELIAC DISEASE; DIET, GLUTEN-FREE; DUODENUM; ENTEROCYTES; FATTY ACID-BINDING PROTEINS; FEMALE; GTP-BINDING PROTEINS; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; TRANSGLUTAMINASES;

EID: 84872683314     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12194     Document Type: Article

References (45)

1. Green PH, Cellier C,. Celiac disease. N Engl J Med 2007; 357: 1731-43.
2. Tack GJ, Verbeek WH, Schreurs MW, et al,. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010; 7: 204-13.
3. Moss SF, Attia L, Scholes JV, et al,. Increased small intestinal apoptosis in coeliac disease. Gut 1996; 39: 811-7.
4. Ciccocioppo R, Di Sabatino A, Parroni R, et al,. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 2001; 115: 494-503.
5. Rubio-Tapia A, Rahim MW, See JA, et al,. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010; 105: 1412-20.
6. Wahab PJ, Meijer JW, Mulder CJ,. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459-63.
7. Lanzini A, Lanzarotto F, Villanacci V, et al,. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009; 29: 1299-308.
8. Hallert C, Grant C, Grehn S, et al,. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther 2002; 16: 1333-9.
9. Tursi A, Brandimarte G, Giorgetti GM,. Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003; 37: 387-91.
10. Vahedi K, Mascart F, Mary JY, et al,. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003; 98: 1079-87.
11. Kaukinen K, Sulkanen S, Maki M, et al,. IgA-class transglutaminase antibodies in evaluating the efficacy of gluten-free diet in coeliac disease. Eur J Gastroenterol Hepatol 2002; 14: 311-5.
12. Dickey W, Hughes DF, McMillan SA,. Disappearance of endomysial antibodies in treated celiac disease does not indicate histological recovery. Am J Gastroenterol 2000; 95: 712-4.
13. Leffler DA, Edwards George JB, et al,. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther 2007; 26: 1227-35.
14. Derikx JP, Evennett NJ, Degraeuwe PL, et al,. Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. Gut 2007; 56: 1473-5.
15. Derikx JP, Poeze M, van Bijnen AA, et al,. Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis. Shock 2007; 28: 544-8.
16. Kanda T, Fujii H, Tani T, et al,. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology 1996; 110: 339-43.
17. Pelsers MM, Hermens WT, Glatz JF,. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35.
18. Derikx JP, Vreugdenhil AC, Van den Neucker AM, et al,. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 2009; 43: 727-33.
19. Levy E, Menard D, Delvin E, et al,. Localization, function and regulation of the two intestinal fatty acid-binding protein types. Histochem Cell Biol 2009; 132: 351-67.
20. Vreugdenhil AC, Wolters VM, Adriaanse MP, et al,. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011; 46: 1435-41.
21. Rostom A, Murray JA, Kagnoff MF,. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 1981-2002.
22. Marsh MN,. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102: 330-54.
23. Rostami K, Kerckhaert J, Tiemessen R, et al,. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol 1999; 94: 888-94.
24. Daum S, Cellier C, Mulder CJ,. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413-24.
25. Cellier C, Delabesse E, Helmer C, et al,. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203-8.
26. Damoiseaux JG, Bouten B, Linders AM, et al,. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 2002; 22: 281-8.
27. Lerner A, Kumar V, Iancu TC,. Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies. Clin Exp Immunol 1994; 95: 78-82.
28. Diosdado B, van Oort E, Wijmenga C,. "Coelionomics": towards understanding the molecular pathology of coeliac disease. Clin Chem Lab Med 2005; 43: 685-95.
29. Crenn P, Vahedi K, Lavergne-Slove A, et al,. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124: 1210-9.
30. Tran CD, Katsikeros R, Manton N, et al,. Zinc homeostasis and gut function in children with celiac disease. Am J Clin Nutr 2011; 94: 1026-32.
31. Grefte JM, Bouman JG, Grond J, et al,. Slow and incomplete histological and functional recovery in adult gluten sensitive enteropathy. J Clin Pathol 1988; 41: 886-91.
32. Cummins AG, Alexander BG, Chung A, et al,. Morphometric evaluation of duodenal biopsies in celiac disease. Am J Gastroenterol 2011; 106: 145-50.
33. Sbarbati A, Valletta E, Bertini M, et al,. Gluten sensitivity and 'normal' histology: is the intestinal mucosa really normal? Dig Liver Dis 2003; 35: 768-73.
34. Stenling R, Fredrikzon B, Engberg S, et al,. Surface ultrastructure of the small intestine mucosa in children with celiac disease. I. Untreated disease and effects of long-term gluten elimination and challenge. Ultrastruct Pathol 1984; 6: 295-305.
35. Bardella MT, Velio P, Cesana BM, et al,. Coeliac disease: a histological follow-up study. Histopathology 2007; 50: 465-71.
36. Koskinen O, Collin P, Lindfors K, et al,. Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. J Clin Gastroenterol 2010; 44: 483-8.
37. Duerksen DR, Wilhelm-Boyles C, Veitch R, et al,. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet. Dig Dis Sci 2010; 55: 1026-31.
38. Hall NJ, Rubin G, Charnock A,. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009; 30: 315-30.
39. Hogberg L, Grodzinsky E, Stenhammar L,. Better dietary compliance in patients with coeliac disease diagnosed in early childhood. Scand J Gastroenterol 2003; 38: 751-4.
40. Tursi A, Brandimarte G, Giorgetti GM, et al,. Endoscopic and histological findings in the duodenum of adults with celiac disease before and after changing to a gluten-free diet: a 2-year prospective study. Endoscopy 2006; 38: 702-7.
41. Kagnoff MF,. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 2007; 117: 41-9.
42. Jabri B, Sollid LM,. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009; 9: 858-870.
43. Rust C, Kooy Y, Pena S, et al,. Phenotypical and functional characterization of small intestinal TcRγδ+T cells in coeliac disease. Scand J Immunol 1992; 35: 459-468.
44. Haines ML, Anderson RP, Gibson PR,. Systematic review: the evidence base for long-term management of coeliac disease. Aliment Pharmacol Ther 2008; 28: 1042-66.
45. Kaukinen K, Peraaho M, Lindfors K, et al,. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007; 25: 1237-45.